Current role checked August 19, 2026 · Recent development

The U.S. Office of Personnel Management identifies Overton as Deputy Director of the White House Domestic Policy Council. Her earlier White House serv...

The U.S. Office of Personnel Management identifies Overton as Deputy Director of the White House Domestic Policy Council. Her earlier White House service includes the 2019–2020 White House Fellows program.

Open this record ↓

August 19, 2026 · status updated after Trump announcement · Directly related claim / evidence

Trump publicly names White House policy aide Heidi Overton to lead the FDA

President Trump publicly named Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, as his choice to lead the Food and Drug Administration on August 19. Reuters and AP reported Trump’s announcement. Senate confirmation is required; FactFlag did not locate a formal nomination-transmission entry in the White House nominations index or Senate nomination records reviewed at this update, so the record does not treat her as confirmed or already serving as FDA commissioner.

Open canonical evidence record →

August 19, 2026 · Recent development

President Trump publicly named Dr. Heidi Overton as his choice to lead the Food and Drug Administration. Reuters and AP report that Senate confirmatio...

President Trump publicly named Dr. Heidi Overton as his FDA choice on August 19. Senate HELP lists her formal nomination as received September 14 and has scheduled a September 24 confirmation hearing. Confirmation and assumption of office remain separate later stages.

Open this record ↓
Biography

Background & current role

Physician and White House domestic-policy official whom President Trump publicly named on August 19, 2026 as his choice to lead the Food and Drug Administration. Senate confirmation is required before she can serve as FDA commissioner.

Current record notes: {'id': 'overton-fda-choice-2026-08-19', 'date': '2026-08-19', 'display_date': 'August 19, 2026', 'subjects': ['health-vaccines', 'office-role'], 'summary': 'President Trump publicly named Dr. Heidi Overton as his choice to lead the Food and Drug Administration. Reuters and AP report that Senate confirmation is required. This profile keeps the announced choice, formal nomination transmission, Senate action and assumption of office as separate procedural stages.'} {'id': 'overton-dpc-role-2026', 'date': '2026-08-19', 'display_date': 'Current role checked August 19, 2026', 'subjects': ['office-role', 'health-vaccines'], 'summary': 'The U.S. Office of Personnel Management identifies Overton as Deputy Director of the White House Domestic Policy Council. Her earlier White House service includes the 2019–2020 White House Fellows program.'}

FactFlag treats this page as a maintained public-record profile. Specific disputed factual claims are evaluated separately, with the original statement, primary evidence, contextual reporting and any material rebuttal shown together.

Role snapshot

Position & relationship

Position / relationship
Deputy Director, White House Domestic Policy Council · Trump-announced FDA nominee
Affiliation / context
White House / FDA nominee
Directory
White House
Profile status
Current White House official; FDA commissioner nomination received by Senate and referred to HELP; confirmation hearing set for September 24, 2026
Service dates
White House Domestic Policy Council: current; FDA commissioner: nominee pending Senate confirmation, not yet serving
Role history & transitions

Documented current/future role notes

  • President Trump publicly named Dr. Heidi Overton as his choice to lead the Food and Drug Administration. Reuters and AP report that Senate confirmation is required. This profile keeps the announced choice, formal nomination transmission, Senate action and assumption of office as separate procedural stages.
  • The U.S. Office of Personnel Management identifies Overton as Deputy Director of the White House Domestic Policy Council. Her earlier White House service includes the 2019–2020 White House Fellows program.
Evidence boundary

Fairness & uncertainty note

This profile distinguishes Overton’s current White House role, Trump’s announced FDA choice, any later formal nomination paperwork, Senate confirmation proceedings, and assumption of office. Criticism or support for her policy views is attributed to the relevant source rather than treated as a factual verdict.

Claims & evidence

Evidence tracker